128 filings
Page 3 of 7
6-K
5n8m0l
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
alaqjglbfn57
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
5pop35nxwx1
29 Oct 21
ObsEva Announces Management Change
5:24pm
6-K/A
hlzjq
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
6c28ox
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
3rb8d 7kicfch1
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
fa6b gyhta
27 Jul 21
Current report (foreign)
6:12am
6-K
orpyz4t2k 0fbdo
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
wsy pg63coxen55
25 May 21
ObsEva Announces Proposed Changes to the Composition of its
5:22pm
6-K
3exi x3z35b5o
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
si8 y1389ngs53scqf
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
jp2id nvc
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
3nalkjtqg3
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
egh ciz6rjaf4b0
31 Mar 21
Current report (foreign)
7:15am
6-K
i97ngnx0quseytfhnhuh
5 Mar 21
Current report (foreign)
8:15am
6-K
kleg ou2f79r4jr2bi5k
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
ayavy7owbisu5az3yz
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
wvn024gnyb3o9wp0
11 Feb 21
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
6:08am
6-K
vun6 extsmw14odlq48
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
bzx 2m8uc13frv9dqkvb
28 Jan 21
ObsEva to Increase Issued Share Capital by Creating
4:26pm